KYNTRA BIO, INC. Cash Flow Statement
KYNB|11 years of annual SEC 10-K data (FY2015-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 11 fiscal years. All figures from audited SEC 10-K filings.
KYNTRA BIO, INC. used $138M in operating cash flow and negative free cash flow of $138M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -3.33 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$47.6M | -$284.2M | -$290.0M | -$189.3M | -$77.0M | -$86.4M | -$120.9M | -$58.1M | -$85.8M | -$59.5M | -$14.9M |
| Depreciation & Amortization | $2.7M | $9.5M | $10.2M | $11.7M | $11.1M | $6.6M | $6.1M | $6.0M | $5.7M | $4.5M | $5.1M |
| Operating Cash Flow | -$138.0M | -$315.0M | -$82.2M | $81.6M | -$78.7M | -$76.1M | -$66.5M | $7.1M | -$18.6M | $22.4M | $25.9M |
| Capital Expenditures | $266.0K | $2.5M | $5.2M | $4.0M | $5.8M | $8.0M | $8.5M | $1.3M | $2.0M | $8.1M | $6.8M |
| Free Cash Flow | -$138.3M | -$317.5M | -$87.4M | $77.6M | -$84.5M | -$84.2M | -$75.0M | $5.9M | -$20.5M | $14.3M | $19.1M |
| FCF Margin | -466.8% | -678.5% | -37.1% | 44.0% | -32.9% | -39.5% | -57.3% | 3.2% | -11.4% | 10.4% | 18.7% |